Allergan, Inc. v. Pharmacia Corp.

I'll research this case carefully before writing.

Case overview — Allergan, Inc. v. Pharmacia Corp., No. 1:01-cv-00141-SLR (D. Del.)

The parties are two branded pharmaceutical operating companies — no NPE/PAE, no university plaintiff on the caption — fighting over the prostaglandin glaucoma franchise. Allergan, Inc. (Irvine, CA) was, and is, an eye-care and specialty-pharma company whose portfolio then included Botox, Alphagan and its newly developed glaucoma drop Lumigan (bimatoprost 0.03%). Pharmacia Corp. (Peapack, NJ), the entity created by the 2000 Monsanto/Pharmacia & Upjohn combination, sold Xalatan (latanoprost), introduced in 1996 and the world's leading branded glaucoma medicine, with 2000 sales of roughly $693 million (LA Times, Mar. 3, 2001; PharmaLetter, Mar. 2, 2001). The technology in suit was therefore not a stray patent being monetized but the core IP of two competing products in the same pharmacological class: Lumigan was the accused product, and Xalatan/latanoprost was the commercial embodiment Allergan needed to design around in order to launch. Notably, Allergan publicly described its molecule as a "prostamide" occurring in ocular tissue rather than a prostaglandin — the factual hook for a non-infringement theory against prostaglandin-derivative claims. This was a pre-launch, brand-versus-brand dispute, not a Hatch-Waxman ANDA case.

**The asserted patent listed for this case is U.S. Patent No. 6,030,999 — "Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension" — issued Feb. 29, 2000 to Johan Stjernschantz and Bahram Resul and assigned to Pharmacia & Upjohn AB

I'll research this case now, keeping in mind the existing summary's caveat that the 6,030,999 patent attribution is uncertain.

Case posture snapshot

Allergan, Inc. v. Pharmacia Corp., No. 1:01‑cv‑00141 (D. Del., Judge Sue L. Robinson) was a pre‑emptive declaratory‑judgment action, not an infringement suit filed by the patentee. Allergan filed it on 2001‑03‑01, two weeks before FDA approved Lumigan, seeking declarations that Lumigan (bimatoprost) did not infringe Pharmacia's Xalatan (latanoprost) patents and that those patents were invalid. It ended not on the merits but by a global business settlement announced 2002‑10‑24/25 and a 2002‑11‑04 dismissal with prejudice. Elapsed time from filing to dismissal: roughly 20 months.

A note refining the existing summary: the 6,030,999 attribution is better supported than the prior narrative suggested, but it is still not confirmed from the complaint itself. See "Patent identification" below.

---

Chronology

1. Filing — 2001‑03‑01 (DJ complaint)

• Allergan sued Pharmacia in the District of Delaware on 2001‑03‑01, seeking a ruling that Lumigan "does not infringe certain patents owned or controlled by Pharmacia" and that those patents "are not valid." Allergan said it acted "having concluded that Pharmacia planned to file a patent infringement suit against Allergan," citing Pharmacia's recent suits against Alcon (Travatan) and Novartis (Rescula). (The Pharma Letter, 2001‑03‑02; L.A. Times, 2001‑03‑03)
• Pharmacia's initial public response was that the action "has not been served upon Pharmacia" and that it therefore had "no information about the identity of the specific patents." (same sources) This is the origin of the uncertainty about the complaint's patent list.
• Docket number and judge: 1:01‑cv‑00141, Judge Robinson. Finnegan Henderson lists the matter as a "declaratory judgment action alleging invalidity and non‑infringement of two patents covering glaucoma drugs," with Allergan as its client. (Finnegan experience page)

2. FDA approval and the litigation crystallizing — 2001‑03‑16

• FDA approved Lumigan on 2001‑03‑16. Pharmacia immediately stated that it believed "the chemical structure of Lumigan violates at least two of Pharmacia's patents" and that it would "vigorously defend" its Xalatan and prostaglandin‑derivative patents. (Healio, 2001‑05‑01; L.A. Times, 2001‑03‑17)
• Allergan's public position was that Lumigan is a "prostamide," not a prostaglandin prodrug — a scientific/claim‑construction theory that later became the central factual battleground in the next decade of Lumigan litigation (see § 8).

3. Answer and counterclaims — 2001 (undocumented in accessible sources)

I found no accessible record of Pharmacia's answer, counterclaims for infringement, or any Rule 12 motion. Given (a) Pharmacia's stated view that Lumigan practiced at least two of its patents, and (b) the case's rapid path to a paid settlement, it is highly likely Pharmacia counterclaimed for infringement (which is what converts a DJ action into a royalty‑bearing settlement), but I cannot source the pleading, its date, or the counterclaim counts. Treat the answer/counterclaim step as unverified. The PACER docket for 1:01‑cv‑00141 would resolve this; the file is archived (pre‑CM/ECF‑era images) and was not retrievable through the sources available here.

4. Parallel proceedings — 2001 to 2002

The Delaware case was one front in a multi‑front war:

• Alcon/Travatan — Pharmacia sued Alcon over Travatan; settled 2002‑10‑09 for prospective royalties on Travatan sales with no upfront payment. (Pharmabiz, 2002‑10‑26; Cowen industry report excerpt)
• Columbia University — co‑party to the settlement. Columbia owned the Bitó prostaglandin patent licensed to Pharmacia. Allergan's 10‑Q records that on 2002‑10‑24 it "entered into a settlement with Pharmacia and Columbia University resolving all intellectual property disputes regarding Lumigan® worldwide." (Allergan 10‑Q excerpt)
• Europe — pending U.K., Dutch, and Swedish actions, which Allergan and Pharmacia were "taking steps to obtain dismissals with prejudice" of after the U.S. dismissal. (same 10‑Q)
• Multiple U.S. venues — the L.A. Times reported settlement of "patent infringement claims in California, Delaware and Europe," and the 10‑Q refers to "the intellectual property lawsuits … that were [commenced] in the United States" (plural). This strongly suggests a second U.S. action, most likely a California suit involving Columbia as plaintiff or DJ defendant. I could not identify that docket; flagging it as a gap. (L.A. Times, 2002‑10‑25)
• Corporate event — Pfizer's acquisition of Pharmacia was announced in July 2002 and closed in April 2003, meaning the settlement counterparty became Pfizer shortly after signing. Contemporary commentary attributes the enforcement posture to "Pfizer/Pharmacia."

5. Pre‑trial motions, Markman, discovery, trial — none reached

• The case settled and was dismissed roughly 20 months after filing, before any merits adjudication. I found no opinion, Markman order, claim‑construction transcript, summary‑judgment ruling, trial, verdict, or JMOL/fee decision in any accessible source. There is no Westlaw/F. Supp. citation for this case, which is consistent with there having been no substantive written ruling.
• Given the timing, a Markman hearing was at most in prospect, not completed. Any discovery that mattered strategically was business/regulatory discovery going to Lumigan's mechanism of action (whether bimatoprost hydrolyzes to the free acid and acts on the FP receptor) — the issue that drove settlement value and that Allergan later litigated for years against generics. I cannot source specific discovery milestones or a discovery cutoff date. Unverified.
• No motion to transfer, no motion to stay (IPR stays did not exist in 2001–02), and no motion to dismiss of substance is documented.

6. Settlement — 2002‑10‑24 (agreement) / 2002‑10‑25 (announcement)

Terms as publicly reported:

Sources: Pharmabiz, 2002‑10‑26; [Healio, 2002

I'll research the docket and counsel appearances for this case.

Bottom line

I could not identify any individual attorney of record for Allergan from a primary source. Only firm-level representation is documented. I am not going to name individual lawyers for this 2001–02 docket, because nothing I found supports specific names.

What is actually sourced

Counsel — plaintiff Allergan, Inc.:

• Finnegan, Henderson, Farabow, Garrett & Dunner LLP (Washington, D.C.; the firm was then known as Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.). Its own experience page states: "Represented Allergan in declaratory judgment action alleging invalidity and non-infringement of two patents covering glaucoma drugs. Allergan, Inc. v. Pharmacia Corp., 1:01-cv-00141, D. Del., Judge Robinson." — https://www.finnegan.com/en/work/experience/allergan-inc-v-pharmacia-corp-1-01-cv-00141-d-del.html. Role on the filing: outside patent counsel; the page does not designate lead vs. of counsel, and it does not name attorneys.

What I could not verify (and why)

• Lead counsel, of counsel, Delaware local counsel, and Allergan in-house counsel: unconfirmed. No named attorney for Allergan appears in any accessible source.
• The case produced no published opinion (it settled before any substantive ruling), so there is no opinion caption listing appearances. CourtListener/RECAP has no 2001 D. Del. docket for this case; the file is in the Delaware federal archives (the Paragraph Four forum notes the 2001 Pharmacia/Allergan declaratory action "was closed in 2002" and that "the court filings are in the Delaware archives"). Finnegan's page likewise gives no attorney names.
• I also could not confirm that U.S. Patent No. 6,030,999 was among the two patents pleaded. That attribution comes only from your case metadata; contemporaneous reporting refers generically to "patents covering Xalatan" and "at least two" Pharmacia patents. Treat the '999 identification as unverified.
• Filings are not sealed as far as I can tell — they are simply not digitized/publicly available.

Adverse-side context (useful for the local-counsel pattern, not attributable to Allergan)

In the related Xalatan ANDA litigation, Pharmacia's Delaware counsel was Morris, Nichols, Arsht & Tunnell (Jack B. Blumenfeld, with Maryellen Noreika, Rodger D. Smith II, Leslie A. Polizoti; Robert D. Rhoad of Dechert of counsel), per Pharmacia Corp. v. Par Pharm., Inc., 417 F.3d 1369 (Fed. Cir. 2005). That confirms Morris Nichols was on the Pharmacia side of the Xalatan patent family at the relevant time; it says nothing about who appeared for Allergan in 01-141.

How to close the gap

1. Pull the docket and D.I. 1 (complaint) for 1:01-cv-00141 (D. Del.) via PACER; if the electronic docket lacks the attorney panel, request the archived file from the Clerk's Office (Wilmington) — the signature block on the complaint and the Rule 7.1/attorney-appearance entries will give names, firms, and bar numbers.
2. Cross-check the consolidated/parallel Pharmacia v. Allergan and Allergan v. Columbia University actions in D. Del. and C.D. Cal. from the same period; appearances there likely overlap.
3. Finnegan's own attorneys who handled the matter can be confirmed through the firm's marketing/experience contacts or the 2001–02 pleadings; I found no firm-published individual attribution.

If you need a defensible counsel table for a filing, I'd recommend we treat only the Finnegan firm-level entry as established and hold individual names pending the archived docket.

I'll research the docket and counsel appearances for this case.

Let me look for the actual docket and any opinions naming defense counsel.

Bottom line

I could not verify any counsel of record for the Pharmacia defendants from online sources, and I am not going to name attorneys I cannot source. The case predates electronic filing in the District of Delaware, and its filings — including any appearances — are in the Delaware federal archives rather than on PACER/CM-ECF. Below is what the record actually establishes, plus the one defense-side attorney whose name is documented in a published opinion.

---

1. The case, as confirmed

Note on PACER availability: the Delaware district's paragraph IV case notes expressly state that the 2001 case's "court filings are in the Delaware archives," which is consistent with D. Del. not having CM/ECF docketing in 2001–02. That is the direct reason no attorney appearance list is retrievable online.

---

2. Defense-side counsel — what is and is not documented

Documented

John P. White, Esq. — lead trial counsel for the Trustees of Columbia University (additional defendant on counterclaim in reply), not for Pharmacia.

• Role: Columbia's lead trial counsel. The court called him exactly that: "Columbia's lead trial counsel, Mr. White," and granted Columbia's motion for a protective order (D.I. 77) barring Allergan from deposing him on the inventorship of the '353 patent.
• Firm: Cooper & Dunham LLP, New York (my general knowledge of his affiliation at that time; not verified in this search — treat as needing confirmation against the 2001–02 letterhead or a contemporaneous court filing).
• Note: Longtime Columbia University patent counsel of record in the Bito/latanoprost patent family; the court treated him as a fact witness on inventorship/inequitable conduct and shielded him from deposition.
• Citation: Allergan Inc. v. Pharmacia Corp., No. Civ. A. 01-141-SLR, 2002 WL 1268047, at *1 (D. Del. May 17, 2002).

Not documented — and flagged as such

• Pharmacia's lead/trial counsel: no name, firm, or office is recoverable from the sources I could reach. I found no opinion, press release, or Law360/Reuters item identifying them.
• Pharmacia's Delaware local counsel: likewise unconfirmed. In this era Pharmacia's Delaware appearances were handled by several different Wilmington firms, so guessing among Connolly Bove Lodge & Hutz, Morris Nichols, Richards Layton, or Potter Anderson would be fabrication. I am not doing it.
• Pharmacia in-house counsel: no appearance identified.
• Whether any Pharmacia attorney was ever formally admitted pro hac vice: unknown; would appear only on the archived paper docket.

I also want to correct a possible trap: search results surface Francis DiGiovanni (Connolly Bove Lodge & Hutz) on a D. Del. brief citing Allergan v. Pharmacia as authority. He was counsel in a different later case that cited this opinion — not counsel here. Do not attribute him to this docket.

---

3. Counsel on the plaintiff side (for contrast / verification trail)

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP — Allergan's opinion counsel (three opinion letters on which Allergan relied to rebut willfulness) and, per Finnegan's own experience page, Allergan's counsel in the DJ action: "Represented Allergan in declaratory judgment action alleging invalidity and non-infringement of two patents covering glaucoma drugs," Allergan, Inc. v. Pharmacia Corp., 1:01-cv-00141, D. Del., Judge Robinson (finnegan.com). Washington, D.C. office. Individual Finnegan partners of record are not named on that page.

---

4. How to close the gap

1. D. Del. Clerk's Office, archived docket for C.A. 01-141-SLR — request the docket sheet and the "Appearance" / pro hac vice entries; this is the only authoritative source for the Pharmacia defense team.
2. Box/folder retrieval of D.I. 1–100 (the May 17, 2002 order references D.I. 77 and D.I. 82, so the file was well developed), and the stipulation of dismissal (likely filed Oct./Nov. 2002) — signature blocks will list every defense firm.
3. Pharmacia Corp. corporate SEC filings / press releases, Oct. 2002 — outside counsel is sometimes acknowledged in settlement announcements (none named in the release I found).
4. Cooper & Dunham archived attorney bios to firm up Mr. White's title and address for the Columbia role.

If you can pull the archived docket or a signed stipulation, I'll identify and profile each defense attorney with firm, office, and patent-litigation history.